{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-025167","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-07-31T12:00:12+00:00","discovered_at":"2026-07-31T12:05:00.326799+00:00","generated_at":"2026-07-31T12:05:26.702897+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Moleculin reports 37% blinded CRc in MIRACLE trial; venetoclax-failed subgroup similar","bullets":["Preliminary blinded CRc of 37% and CR of 24% in 62 evaluable R/R AML subjects.","Among 30 patients who failed prior venetoclax, CRc also 37% (3x published salvage rate of ~13%).","No cardiotoxicity observed; enrollment at 74 of 90; final Part A treatment expected Sept 2026.","Unblinded Part A results expected Dec 2026–Feb 2027; prior unblinded Annamycin arms showed CRc 50-57% vs control 29%."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-025167","json":"https://secwatch.observer/filing/0001437749-26-025167.json","markdown":"https://secwatch.observer/filing/0001437749-26-025167.md","text":"https://secwatch.observer/filing/0001437749-26-025167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926025167/0001437749-26-025167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926025167/mbrx20260729_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T12:05:26.702897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}